Vyas

Vyas is a biotechnology company focused on developing a new class of medicines that target the root cause of metabolic disease and aging. By leveraging a proprietary platform that integrates high-resolution metabolomics with machine learning, the company maps the human metabolome to identify novel therapeutic targets and biomarkers. Their approach centers on metabolic reprogramming, aiming to restore cellular function and extend healthspan through the development of targeted small molecule therapies. Currently in the pre-clinical stage, Vyas is advancing a pipeline of programs focused on high-need indications in oncology, metabolic disorders, and age-related conditions. The company is headquartered in San Francisco and maintains a significant research presence in London.